Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Ningbo
Clinical trial register · China

Clinical Trials in Ningbo, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing5576 Shanghai3879 Guangzhou3345 Hangzhou1819 Wuhan1343
All 625 locations
Target enrolment
to

Trials with a site in Ningbo

151 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Zhejiang Provincial Center for Disease Control and Prevention
Phase 4
200
Ningbo
2026-10-20
Recruiting
Hoffmann-La Roche
Phase 3
325
Guangzhou, Mianyang, Changde, Huizhou, Ningbo, Sanmenxia, Shanghai, Xiamen
2026-10-16
Recruiting
Eli Lilly and Company
Phase 3
1,000
Changchun, Jinan, Luoyang Shi, Nanjing, Ningbo, Shijiazhuang, Tianjin
2026-10-16
Recruiting
Ningbo Medical Center Lihuili Hospital
Not applicable
27
Ningbo
2026-10-07
Recruiting
Janssen Research & Development, LLC
Phase 2
440
Beijing, Changzhou, Ningbo, Taiyuan
2026-10-05
Recruiting
Beijing Sungen Biomedical Technology Co., Ltd
Phase 2
129
Chengdu, Guizhou, Hangzhou, Hefei, Luoyang, Nanchang, Nanjing, Ningbo
2026-09-30
Recruiting
Axter Therapeutics (Beijing) Co., Ltd
Phase 1
105
Guangzhou, Changsha, Shanghai, Ningbo
2026-09-24
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2/3
150
Nanning, Hangzhou, Huzhou, Jiaxing, Ningbo, Taizhou, Beijing
2026-08-27
Recruiting
Eli Lilly and Company
Phase 3
2,001
Chengdu, Hefei, Jinan, Luoyang Shi, Nanjing, Ningbo, Qinhuangdao Shi, Tianjin
2026-08-26
Recruiting
AstraZeneca
Phase 3
500
Beijing, Changchun, Chengdu, Guangzhou, Huzhou, Nanjing, Ningbo
2026-08-24
Not yet open
Ningbo No. 1 Hospital
Not applicable
106
Ningbo
2026-07-20
Recruiting
Safety and Efficacy of Eculizumab in High-risk TA-TMA
NCT07707687Transplant-Associated Thrombotic Microangiopathy (TA-TMA)
First Affiliated Hospital of Zhejiang University
Phase 2
24
Changsha, Hangzhou, Jinhua, Ningbo, Wenzhou
2026-07-10
Recruiting
Single-Dose vs. Divided-Dose G-CSF for Stem Cell Mobilization in Healthy Allogeneic Donors
NCT07692841Healthy Hematopoietic Stem Cell Donor, Healthy Allogeneic Hematopoietic Stem Cell Donor
DrugG-Csf
First Affiliated Hospital of Zhejiang University
Phase 3
560
Changsha, Hangzhou, Jinhua, Ningbo, Wenzhou
2026-07-10
Recruiting
Hoffmann-La Roche
Phase 3
300
Zhengzhou, Xianyang, Ningbo, Beijing, Changchun, Hefei, Herbin, Huai'an
2026-07-03
Active, closed
Boehringer Ingelheim
Phase 2
344
Huzhou, Jinan, Luoyang, Nanjing, Ningbo, Qinhuangdao, Tianjin, Yichang
2026-06-30
Recruiting
Novartis Pharmaceuticals
Phase 4
36
Guangzhou, Shijiazhuang, Chengdu, Hangzhou, Ningbo, Wenzhou, Beijing, Shanghai
2026-06-01
Recruiting
Ningbo No.2 Hospital
Observational
500
Ningbo
2026-06-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
100
Nanjing, Hangzhou, Ningbo
2026-05-20
Recruiting
First Affiliated Hospital of Ningbo University
Not applicable
186
Ningbo
2026-05-15
Not yet open
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
264
Fuzhou, Hangzhou, Huzhou, Jinhua, Ningbo, Wenzhou
2026-05-07
Not yet open
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
118
Hangzhou, Fuzhou, Huzhou, Jinhua, Ningbo, Wenzhou
2026-05-01
Not yet open
Ningbo Medical Center Lihuili Hospital
Not applicable
204
Ningbo
2026-05-01
Recruiting
Boehringer Ingelheim
Phase 2
405
Beijing, Changchun, Changsha, Guangzhou, Linfen, Nanjing, Ningbo, Shanghai
2026-04-20
Active, closed
A Study of CS060380 Tablets in Patients With MASH and Obesity
NCT07466017Metabolic Dysfunction-associated Steatohepatitis (MASH), Obesity
Cascade Pharmaceuticals, Inc
Phase 2
130
Hefei, Guangzhou, Shijiazhuang, Nanjing, Shanghai, Hangzhou, Ningbo, Wenzhou
2026-04-02
Recruiting
Grid eXplore Mapping Study
NCT07421076Paroxysmal Atrial Fibrillation (PAF)
Abbott Medical Devices
Not applicable
200
Jinan, Chengdu, Hangzhou, Ningbo, Beijing
2026-04-02
Not yet open
Ningbo No.2 Hospital
Early Phase 1
156
Hangzhou, Ningbo
2026-03-31
Not yet open
HEM-SURVIVE: Structuralized Follow-up for Childhood Hematological Malignancy Survivors
NCT07483749Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Lymphoma, Leukemia
The Children's Hospital of Zhejiang University School of Medicine
Observational
400
Hangzhou, Ningbo
2026-03-25
Recruiting
Hoffmann-La Roche
Phase 3
1,600
Cangzhou, Kaifeng, Xuzhou, Zhenjiang, Xianyang, Jinan, Ningbo, Beijing
2026-03-23
Recruiting
Beijing Tiantan Hospital
Not applicable
376
Dongguan, Guangdong, Zhengzhou, Jinan, Jining, Ningbo, Beijing
2026-03-13
Recruiting
Pfizer
Phase 1/2
132
Beijing, Nanjing, Tianjin, Ningbo
2026-03-11
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
528
Shanghai, Taiyuan, Hangzhou, Huzhou, Jinhua, Ningbo, Shanhu
2026-02-23
Recruiting
Microbiome and Enteric Signatures in Sepsis-associated Hepatorenal Injury
NCT07735182Sepsis, Acute Kidney Injury Due to Sepsis, Gastrointestinal Microbiome, Sepsis-Associated Liver Injury
First Affiliated Hospital of Zhejiang University
Observational
1,000
Hangzhou, Jiaxing, Ningbo, Taizhou
2026-02-15
Recruiting
Pfizer
Phase 1/2
224
Beijing, Chongqing, Wuhan, Changsha, Nanjing, Jinan, Ningbo
2026-02-10
Recruiting
Sir Run Run Shaw Hospital
Phase 4
846
Hangzhou, Huzhou, Ningbo
2026-02-09
By invitation
CHU Dual-Energy Ablation in Ventricular Arrhythmia
NCT07503769Premature Ventricular Contractions, Ventricular Tachycardia
Shanghai MicroPort EP MedTech Co., Ltd.
Not applicable
10
Ningbo
2026-02-03
Recruiting
Multicenter Prospective Non-randomized Controlled Study of Ella Photodynamic Therapy for Cervical HSIL/CIN2
NCT07306260HSIL, High Grade Squamous Intraepithelial Lesion, CIN 2, HPV (Human Papillomavirus)-Associated, Photodynamic Therapy (PDT)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
560
Hangzhou, Ningbo, Shaoxing
2026-01-29
Not yet open
Ningbo Medical Center Lihuili Hospital
Observational
300
Ningbo
2026-01-25
Recruiting
Shanghai Mental Health Center
Observational
121
Suzhou, Xuzhou, Shanghai, Hangzhou, Ningbo
2026-01-24
Not yet open
LLL vs. SDL for LBBP: A Non-inferiority RCT
NCT07378124Bradycardia, Conduction Block, Atrioventricular
Ningbo No.2 Hospital
Not applicable
288
Ningbo
2026-01-24
Recruiting
Multicenter Prospective Non-randomized Controlled Study of ALA-PDT for LSIL With HPV16/18 Infection
NCT07306247HPV-16/18, Photodynamic Therapy (PDT), LSIL, Low Grade Squamous Intraepithelial Lesion
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
225
Hangzhou, Ningbo, Shaoxing
2026-01-21
Active, closed
Janssen Research & Development, LLC
Phase 2
157
Beijing, Changsha, Changzhou, Chengdu, Chongqing, Hangzhou, Ningbo, Shanghai
2026-01-15
Not yet open
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
848
Beijing, Huangshi, Wuhan, Xiangyang, Hangzhou, Jiaxing, Ningbo
2026-01-01
Not yet open
Lidocaine Decreases Postoperative Lung Cancer Reoccurance and Metatasis Risk
NCT07347977Non-Small Cell Lung Cancer, Recurrence, Survival Analysis
First Affiliated Hospital of Ningbo University
Not applicable
1,400
Ningbo
2026-01-01
Not yet open
Ningbo Eye Hospital
Not applicable
180
Ningbo
2025-12-02
Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Observational
10,000
Zunyi, Jiangxi, Shanghai, Ningbo
2025-12-01
Not yet open
Shanghai Changzheng Hospital
Observational
1,100
Beijing, Guangzhou, Nanjing, Suzhou, Shanghai, Chengdu, Ningbo
2025-12
Recruiting
Sanofi
Observational
1,000
Beijing, Shenzhen, Changsha, Xi’an, Chengdu, Hangzhou, Ningbo, Chongqing
2025-11-17
Recruiting
Eli Lilly and Company
Phase 2
222
Beijing, Chengdu, Chongqing, Hangzhou, Linhai, Ningbo, Shenzhen
2025-11-03
Recruiting
The Affiliated People's Hospital of Ningbo University
Phase 3
92
Ningbo
2025-10-31
Not yet open
First Affiliated Hospital of Ningbo University
Observational
4,000
Ningbo
2025-10-21
By invitation
First Affiliated Hospital of Ningbo University
Not applicable
86
Ningbo
2025-10-06
Recruiting
Sanofi
Phase 4
218
Chengdu, Guangzhou, Hangzhou, Harbin, Ningbo, Xiamen
2025-09-22
Recruiting
Janssen Research & Development, LLC
Phase 3
220
Beijing, Chengdu, Guangzhou, Nanjing, Ningbo, Tianjin, Wenzhou, Wuhan
2025-09-10
Not yet open
Shanghai Chest Hospital
Not applicable
465
Beijing, Zhengzhou, Nanjing, Ningbo, Shanghai
2025-09-01
Recruiting
Deep Learning CAD Screening on Chest CT
NCT07181512Coronary Artery Disease, Coronary Artery Stenosis Stent
Yifan Guo
Observational
200
Hangzhou, Ningbo
2025-09-01
Recruiting
Ningbo Medical Center Lihuili Hospital
Not applicable
76
Ningbo
2025-09-01
Recruiting
Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer
NCT07117045Pancreatic Cancer, Intraductal Papillary Mucinous Neoplasm, High-grade Pancreatic Intraepithelial Neoplasia, PDAC - Pancreatic Ductal Adenocarcinoma
Changhai Hospital
Observational
400,000
Shanghai, Jiaxing, Ningbo
2025-08-15
Recruiting
Immune Status and Disease Control of Inflammatory Airway Diseases
NCT07493629Airway Inflammation, Chronic Obstructive Pulmonary Disease (COPD), Asthma (Diagnosis), Bronchiectasis
First Affiliated Hospital of Ningbo University
Observational
200
Ningbo
2025-08-01
Recruiting
Effects of Environmental Fungal Exposure on Bronchial Asthma, ABPA and Bronchiectasis
NCT07313904Environmental Exposure, Asthma, Bronchiectasis, ABPA
First Affiliated Hospital of Ningbo University
Observational
125
Ningbo
2025-07-23
Recruiting
First Affiliated Hospital of Ningbo University
Observational
120
Ningbo
2025-07-09
Active, closed
Sanofi
Phase 2
105
Huizhou, Guangzhou, Nanjing, Suzhou, Wuxi, Shanghai, Hangzhou, Ningbo
2025-07-07
Not yet open
DCB for CAD With Type 2 Diabetes
NCT07009938Coronary Artery Disease, Diabete Type 2
Shanghai 10th People's Hospital
Not applicable
1,000
Kaifeng, Luoyang, Zhengzhou, Shanghai, Yibin, Ningbo
2025-07-01
Recruiting
First Affiliated Hospital of Ningbo University
Not applicable
380
Hefei, Harbin, Ningbo, Ninghai, Taizhou
2025-06-17
Recruiting
Anhui Provincial Hospital
Observational
600
Hefei, Suzhou, Ningbo
2025-06-01
Recruiting
Standardized Implementation and Quality Assessment System for Confocal Enteroscopy
NCT07363291Confocal Enteroscopy, Quality Assessment System, Standardized Implementation
Shanghai Jiao Tong University School of Medicine
Observational
600
Hefei, Ningbo, Kashgar, Shanghai
2025-06-01
Not yet open
PFA-based Bi-atrial Maze-like Catheter Ablation for PeAF
NCT06952023Atrial Fibrillation, Persistent Atrial Fibrillation
The First Affiliated Hospital of Dalian Medical University
Not applicable
390
Nanjing, Dalian, Ningbo
2025-06
Recruiting
Peking Union Medical College Hospital
Observational
60
Ningbo
2025-05-24
Recruiting
Ningbo Medical Center Lihuili Hospital
Not applicable
28
Ningbo
2025-05-01
Recruiting
Accelerated Biological Aging is Associated With Increased Risk of T2DM in the MASLD Population
NCT06984510Type 2 Diabetes Mellitus (T2DM), Metabolic Dysfunction-Associated Steatotic Liver Disease, Biological Age
Ningbo No. 1 Hospital
Observational
2,720
Ningbo
2025-04-01
By invitation
Metabolically Healthy Obesity Increases the Risks of MASLD and Hyperuricemia
NCT07001865Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolically Healthy Obesity, Hyperuricemia
Ningbo No. 1 Hospital
Observational
17,040
Ningbo
2025-04-01
Active, closed
Screening and Intervention of MASLD in Children
NCT06905795MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Children
Ningbo No. 1 Hospital
Not applicable
270
Ningbo
2025-04-01
By invitation
First Affiliated Hospital of Ningbo University
Observational
100
Ningbo
2025-03-30
Recruiting
Comparing Different Diameter fURSs With Similar RESDs for the Treatment of Upper Urinary Tract Stones
NCT06987760Ureter Injury, Urolithiasis; Lower Urinary Tract, Efficacy, Self
Ningbo No. 1 Hospital
Not applicable
206
Ningbo
2025-03-19
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
51
Hangzhou, Dongyang, Huzhou, Jiaxing, Lishui, Ningbo, Quzhou, Shaoxing
2025-03-11
By invitation
First Affiliated Hospital of Ningbo University
Phase 4
20
Ningbo
2025-03-01
Recruiting
CHiR Therapy for Elderly DLBCL Intolerant to Chemo
NCT06764017Diffuse Large B-Cell Lymphoma
First Affiliated Hospital of Ningbo University
Phase 2
30
Ningbo
2025-02-01
Recruiting
First Affiliated Hospital of Ningbo University
Phase 2
50
Ningbo
2025-01-15
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
38
Yangzhou, Shanghai, Hangzhou, Huzhou, Jiaxing, Ningbo, Wenzhou
2025-01-06
By invitation
First Affiliated Hospital of Ningbo University
Phase 4
100
Ningbo
2025-01-01
By invitation
Metabolic Characteristics of Plasma OxPLs in STEMI Patients.
NCT07382700STEMI - ST-segment Elevation Myocardial Infarction
First Affiliated Hospital of Ningbo University
Observational
240
Ningbo
2025-01-01
By invitation
First Affiliated Hospital of Ningbo University
Phase 4
200
Ningbo
2025-01-01
Not yet open
Akeso
Phase 2
24
Dongguan, Guangzhou, Shenzhen, Changsha, Ningbo
2024-12-30
By invitation
IIT Study on the Use of Medical Bio Glue for Repairing Meniscus Tears
NCT06878794Unilateral Meniscus Tear of the Knee Joint
First Affiliated Hospital of Ningbo University
Not applicable
60
Ningbo
2024-12-25
Recruiting
First Affiliated Hospital of Ningbo University
Not applicable
216
Harbin, Hefei, Jingzhou, Ningbo, Ninghai, Taizhou
2024-12-13
By invitation
First Affiliated Hospital of Ningbo University
Not applicable
20
Ningbo
2024-12-01
Recruiting
Multicenter iTBS Neuromodulation for PTSD Treatment
NCT06434766Posttraumatic Stress Disorder
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
140
Shanghai, Hangzhou, Ningbo
2024-10-30
Recruiting
Fudan University
Phase 4
756
Harbin, Changzhou, Nanjing, Yangzhou, Shanghai, Hangzhou, Ningbo
2024-10-18
Active, closed
Novartis Pharmaceuticals
Phase 2
201
Nanning, Zhengzhou, Chengdu, Ningbo, Beijing, Tianjin
2024-10-09
Recruiting
First Affiliated Hospital of Ningbo University
Not applicable
180
Ningbo
2024-08-14
Recruiting
Ningbo Medical Center Lihuili Hospital
Not applicable
30
Ningbo
2024-08-07
Recruiting
AI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening Cohort
NCT06638866Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Intraepithelial Neoplasias, Intraductal Papillary Mucinous Neoplasm
Changhai Hospital
Observational
5,000
Shanghai, Jiaxing, Ningbo
2024-08-03
Recruiting
The Affiliated People's Hospital of Ningbo University
Phase 3
99
Dongyang, Hangzhou, Huzhou, Jiaxing, Jinhua, Lishui, Ningbo, Shaoxing
2024-08-01
Recruiting
The Affiliated People's Hospital of Ningbo University
Phase 3
99
Dongyang, Hangzhou, Huzhou, Jiaxing, Jinhua, Lishui, Ningbo, Shaoxing
2024-08
Recruiting
Peking University People's Hospital
Observational
30
Beijing, Chengdu, Guangdong, Kunming, Nanjing, Nanning, Nanyang, Ningbo
2024-07-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
222
Hangzhou, Ningbo, Wenzhou
2024-06-25
Recruiting
Second Affiliated Hospital of Wenzhou Medical University
Not applicable
1,860
Dongyang, Hangzhou, Jinhua, Lishui, Ningbo, Quzhou, Taizhou, Wenling
2024-06-19
Not yet open
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
216
Huzhou, Lishui, Meicheng, Ningbo, Shaoxing, Taizhou
2024-05-31
Recruiting
Shanghai Jiao Tong University School of Medicine
Phase 2/3
90
Hefei, Fuzhou, Shanghai, Ningbo
2024-05-21
Not yet open
Changhai Hospital
Not applicable
200
Guangzhou, Suzhou, Wuxi, Ningbo, Shanghai
2024-05-01
Active, closed
Evolve China PMCF Study
NCT06368622Intracranial Aneurysm
Stryker Neurovascular
Observational
500
Beijing, Changchun, Fuzhou, Guangzhou, Kunming, Nanyang, Ningbo, Qingdao
2024-04-24
Recruiting
Peking Union Medical College Hospital
Observational
3,000
Hefei, Beijing, Nanning, Zhengzhou, Henan, Ningbo, Shanghai, Wuhan
2024-04-19
Active, closed
argenx
Phase 3
119
Beijing, Changchun, Chongqing, Fuzhou, Guangxi, Guangzhou, Guiyang, Ningbo
2024-04-16
Recruiting
First Affiliated Hospital of Ningbo University
Not applicable
260
Ningbo
2024-04-01
Recruiting
Fudan University
Phase 2
210
Fuzhou, Nantong, Shanghai, Hangzhou, Ningbo
2024-03-04
Recruiting
Ningbo Medical Center Lihuili Hospital
Observational
800
Ningbo
2024-01-24
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Phase 2
33
Nanjing, Chengdu, Ningbo
2024-01-19
Recruiting
First Affiliated Hospital of Wenzhou Medical University
Phase 4
1,500
Ningbo, Rui’an, Wenzhou, Yueqing
2024-01-01
Recruiting
Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05)
NCT05872685Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Proficient Mismatch Repair
Yu jiren
Phase 2
314
Hangzhou, Lishui, Ningbo, Taizhou
2023-12-24
Recruiting
Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer
NCT05737303Epithelial Ovarian Carcinoma Stage III, Epithelial Ovarian Carcinoma Stage IV, Fallopian Tube Carcinoma Stage III, Fallopian Tube Carcinoma Stage IV
Women's Hospital School Of Medicine Zhejiang University
Phase 3
538
Guangzhou, Ji'nan, Hangzhou, Ningbo, Wenzhou
2023-11-27
Recruiting
A Registry Study of Intracranial Atherosclerotic Stenosis Treatment by Intracranial Drug-eluting Stenting in China
NCT05692882Intracranial Arteriosclerosis, Stenosis Artery, Drug-Eluting Stents, Intracranial Artery Stenosis
Sino Medical Sciences Technology Inc.
Not applicable
1,000
Chenzhou, Ganzhou, Jinhua, Ningbo, Shanxi
2023-11-16
Active, closed
Liaoning Chengda Biotechnology CO., LTD
Phase 4
600
Jiaxing, Jinhua, Ningbo, Quzhou
2023-11-11
Recruiting
Mao Jianhua
Phase 3
140
Wuhan, Nanjing, Kunming, Hangzhou, Ningbo, Wenzhou, Beijing, Shanghai
2023-11-01
Active, closed
Janssen Research & Development, LLC
Phase 3
420
Beijing, Changchun, Chengdu, Guangzhou, Jinan, Ningbo, Shenyang, Wuhan
2023-08-31
Not yet open
Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
NCT05970627Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Epstein-Barr Virus-Associated Gastric Carcinoma
Yu jiren
Phase 2
30
Hangzhou, Huzhou, Lishui, Ningbo, Taizhou
2023-07-28
Recruiting
Peking University
Not applicable
22,032
Ningbo
2023-07-06
Recruiting
Sir Run Run Shaw Hospital
Not applicable
422
Hangzhou, Huzhou, Jinhua, Lishui, Ningbo, Quzhou, Shaoxing, Taizhou
2023-07-01
Recruiting
Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
NCT05729646Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Mismatch Repair Deficiency
Yu jiren
Phase 2
90
Hangzhou, Huzhou, Lishui, Ningbo, Taizhou
2023-05-31
Active, closed
Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
NCT05715931Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, HER2-positive Gastric Cancer
Yu jiren
Phase 2
30
Hangzhou, Huzhou, Lishui, Ningbo, Taizhou
2023-05-30
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
118
Ningbo
2023-04-13
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
158
Hangzhou, Jiaxing, Jinhua, Ningbo, Yiwu
2023-04-01
Recruiting
Combined Screening for Gastrointestinal Tumors
NCT06478030Gastrointestinal Tumors
Zhejiang Cancer Hospital
Observational
200,000
Jinhua, Ningbo
2023-03-01
Not yet open
Zhejiang University
Phase 3
38
Shanghai, Hangzhou, Ningbo
2023-03
Recruiting
Shanghai Tong Ren Hospital
Phase 2
58
Changzhou, Chengdu, Ch’ang-ch’un, Ha’erbin, Hefei, Jiaxing, Lanzhou, Ningbo
2023-02-20
Active, closed
AstraZeneca
Phase 2
51
Beijing, Chengdu, Fuzhou, Guangzhou, Kunming, Ningbo, Shijiazhuang, Suzhou
2023-02-09
Recruiting
Clinical Study of OR for Second-line Treatment of Refractory MZL
NCT06134284OR Regimen for Relapsed/Refractory Marginal Zone Lymphoma
Lixia Sheng
Phase 4
39
Hangzhou, Ningbo
2023-01-02
Recruiting
Ningbo No. 1 Hospital
Phase 1
24
Hangzhou, Ningbo
2022-12
Active, closed
AstraZeneca
Phase 2
47
Beijing, Changsha, Chongqing, Hangzhou, Jinan, Kunming, Nanchang, Ningbo
2022-11-15
Active, closed
Kaikai QIU
Not applicable
100
Ningbo
2022-10-21
Active, closed
Ningbo No. 1 Hospital
Not applicable
1,627
Ningbo
2022-09-01
Active, closed
Ningbo No. 1 Hospital
Not applicable
331
Ningbo
2022-09-01
Recruiting
Zhejiang Provincial People's Hospital
Phase 2
80
Qingdao, Hangzhou, Ningbo, Tianjin, Wenzhou
2022-09-01
Recruiting
Zhejiang Cancer Hospital
Phase 2
100
Hanzhou, Ningbo
2022-08-03
Recruiting
Zhejiang Cancer Hospital
Phase 2
41
Hangzhou, Jiaxing, Jinhua, Lishui, Ningbo, Quzhou
2022-08-01
Recruiting
PROfiling Based Endometrial Cancer Adjuvant Therapy
NCT05179447Endometrial Cancer Stage I, Endometrial Cancer Stage II
Women's Hospital School Of Medicine Zhejiang University
Not applicable
590
Wuhan, Jinan, Hangzhou, Beijing, Changsha, Guangzhou, Ningbo, Shanghai
2022-01-24
Recruiting
Immune Score Based Radiomics in Nasopharyngeal Carcinoma
NCT05126160Nasopharyngeal Carcinoma
Zhejiang Cancer Hospital
Observational
494
Wuhan, Ningbo, Wenzhou, Hangzhou
2021-11-05
Recruiting
Zhejiang Cancer Hospital
Phase 3
455
Hangzhou, Jinhua, Lishui, Ningbo, Taizhou, Wanzhou
2021-08-02
Recruiting
Ningbo Medical Center Lihuili Hospital
Not applicable
60
Ningbo
2021-05-01
Active, closed
Ningbo Medical Center Lihuili Hospital
Observational
500
Ningbo
2021-01-01
Active, closed
Hecheng Li M.D., Ph.D
Phase 3
244
Shanghai, Hangzhou, Ningbo
2020-11-10
Recruiting
Abbott Vascular Medical Device Registry
NCT04573660Acute Myocardial Infarction, Restenoses, Coronary, Coronary Artery Lesions, Venous Embolism
Abbott Medical Devices
Observational
3,784
Xi'an, Jinhua, Ningbo
2020-10-25
Active, closed
First Affiliated Hospital of Zhejiang University
Phase 3
232
Changsha, Chongqing, Hangzhou, Nanjing, Ningbo, Suzhou
2020-09-01
Active, closed
Beijing Airdoc Technology Co., Ltd.
Not applicable
50
Ningbo
2020-05-13
Active, closed
Janssen Research & Development, LLC
Phase 3
765
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanjing, Ningbo, Shanghai
2019-01-25
Active, closed
Ningbo Schizophrenia Cohort
NCT06370793Schizophrenia
Ningbo University
Observational
26,899
Ningbo
2018-07-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
797
Tianjin, Beijing, Guangzhou, Changsha, Shanghai, Xi’an, Hangzhou, Ningbo
2018-04-24
Active, closed
Ningbo Maternity-Child Linked Database Study
NCT06422130Pregnant Women, Children
Ningbo University
Observational
325,596
Ningbo
2016-10-01
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,503
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing, Ningbo
2015-11-19
Rows per page Showing 1–151 of 151
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/ningbo

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 151 of those studies with a site in Ningbo.

How many clinical trials are recruiting in Ningbo?

90 of the 151 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 23 have not yet opened recruitment, 28 are active but closed to new participants, and 10 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Ningbo), 151 studies
PhaseStudiesRecruitingShare
Not applicable452129.8%
Observational332221.9%
Phase 2302019.9%
Phase 3241415.9%
Phase 41277.9%
Phase 1221.3%
Phase 1/2221.3%
Phase 2/3221.3%
Early Phase 1100.7%

Most active sponsors

Lead sponsors with the most studies (Ningbo)
Lead sponsorStudiesRecruiting
First Affiliated Hospital of Ningbo University2010
Second Affiliated Hospital, Zhejiang University, School of Medicine1510
Ningbo Medical Center Lihuili Hospital107
Ningbo No. 1 Hospital83
Janssen Research & Development, LLC62
Zhejiang Cancer Hospital55
First Affiliated Hospital of Zhejiang University43
Sanofi42
Yu jiren42
AstraZeneca31
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.